18 ECCO - 40 ESMO European Cancer Congress/media/Documents/ECCO sections/Vienna 2… · 2 3 ecco 18 - esmo 40 - efi431580 c8054 c3045 - preliminary announcement ecco 18 - esmo 40

18th ECCO - 40th ESMO

European Cancer CongressReinforcing Multidisciplinarity

VIENNA, AUSTRIA, 25 - 29 SEPTEMBER 2015

18

SIOPSIOP Europethe European Society for Paediatric Oncology35

www.europeancancercongress.org

PRELIMINARY ANNOUNCEMENT

2 3

ECCO 18 - ESMO 40 - European Cancer Congress - PRELIMINARY ANNOUNCEMENT ECCO 18 - ESMO 40 - European Cancer Congress - PRELIMINARY ANNOUNCEMENT

Save the Dates 18th ECCO - 40th ESMO European Cancer Congress25 – 29 September 2015

Registration opens 1 October 2014

Advance programme available January 2015

Abstract submission opens 26 January 2015

Abstract submission closes 28 April 2015

Accommodation booking deadline 22 June 2015

Late-breaking abstract submission opens 22 July 2015

Late-breaking abstract submission closes 5 August 2015

EXHIBITION DEADLINES

Application for partners with priority status 1 August 2014

Release of exhibition space assignments September 2014

Early rate deadline 31 December 2014

Receipt of balance of payment 15 June 2015

Receipt of complete stand drawings 31 July 2015

SATELLITE SYMPOSIA DEADLINES

Application for partners with priority status 1 August 2014

Release of satellite symposia slots assignments September 2014

Receipt of the draft programme 15 May 2015

Receipt of balance of payment 15 June 2015

Receipt of final programme 31 July 2015

GROUP REGISTRATION DEADLINES

Early rate group registrations 7 April 2015

Regular rate group registrations 4 August 2015

Receipt of complete group participants’ details 4 August 2015

Chairs’ Introduction The European Cancer Congress (ECC2015) is undoubtedly the largest European platform for presenting ground-breaking data to a global audience.

We are on a path where each Congress sets new records – ECC2011 in Stockholm and ECC2013 in Amsterdam both attracted record numbers of participants and submitted abstracts. ECC2013 in Amsterdam registered 16% growth in delegates and a massive 38% increase in the number of submitted abstracts compared to our event in Stockholm.

Our late-breaking submission policy is specially designed to ensure the Congress embraces all promising new developments to ensure a very advanced, forward-looking scientific programme. Topics of the greatest interest to a multidisciplinary audience are presented by the very experts who work on them.

The European Cancer Congress is now giving fresh impetus to its unique philosophy of collaborative innovation to improve outcomes and find new solutions to pressing issues. We have designed more integrated sessions bringing about dialogue and debate in overlapping areas of scientific research. The programme is therefore more streamlined, with fewer tracks, facilitating an even more productive experience for delegates.

The European Cancer Congress remains the only European cancer meeting with a dedicated Oncopolicy track. The Oncopolicy Forum in Amsterdam tackled topics including research, personalised medicine and care, organisation of specialised care, and translation of evidence into policy. The recommendations derived from these discussions will be revisited at the Oncopolicy Forum in Vienna in 2015.

Our Patient Advocacy Track will carry forward its work in highlighting key issues for patients and survivors and exploring partnerships with all stakeholders in the oncology community.

ECC2015 will again be the largest CME ACOE accredited event in Europe. In addition, we have enriched the programme with new elements over and above those of CME – we envisage unique mentorship opportunities and various other ways of enhancing knowledge and skills beyond the scientific programme.

There is a single aim behind all these efforts – to make the European Cancer Congress the most powerful of platforms for improving cancer care, outcomes and quality of life for all people with cancer.

This vision brought us to Vienna – a vibrant city and such a natural host of ECC2015. Vienna’s track record as a leader in medical thought and practice speaks for itself – its historic contribution has made its mark in key areas like radiotherapy, clinical diagnosis and public health to name a few.

We look forward to welcoming you to Vienna!

Martine Piccart, Congress Chair, ECCO President

Rolf A. Stahel, ESMO President

Peter Naredi, Scientific Co-Chair

Elisabeth De Vries, Scientific Co-Chair

Christoph Zielinski, National Organising Committee Chair

4 5


Provisional Congress Programme at a Glance

Friday,25 September 2015

Saturday,26 September 2015

Sunday,27 September 2015

Monday,28 September 2015

Tuesday,29 September 2015

11:00 - 19:00Satellite

Symposia

07:45 - 08:30 Teaching Lectures

08:00-08:45Teaching Lectures/Highlights Sessions

08:00 - 09:00Poster Discussions

08:00 - 08:45 Teaching Lectures/Highlights Session

08:45 - 10:15Opening Session

09:15 - 11:15Proffered Papers/

Scientific Symposia/Integrated Sessions/Oncopolicy Forum/

Poster Sessions

09:00 - 11:00Proffered Papers/

Scientific Symposia/Integrated Sessions/

Educational Symposia/

Oncopolicy Forum

09:30 - 16:30Exhibition

11:15 - 12:15Special Sessions/

Debates/Oncopolicy Forum

10:30 - 12:30Proffered Papers/Society Sessions/

Scientific Symposia/Patient Advocacy

Session


Debates/Tumour Board

Sessions



Session/Oncopolicy Forum

12:30 - 13:30Take Home

Message

13:00 - 14:30Patient Advocacy Sessions/Oncopolicy Forum/

Young Oncologists Worskshops/Non CME Activities/Satellite Symposia

13:00 - 14:30Young Oncologists

Worskshops/Non CME Activities/Satellite Symposia

14:30 - 16:30Presidential Session


Debate




Sessions/Patient Advocacy

Session



Debates

16:45-18:45Educational Symposia/

Poster Sessions16:45-18:15

Scientific Symposia

16:45-18:45Educational Symposia/

Integrated Sessions/Poster Sessions

17:00-18:30Scientific Symposia

16:45-18:45Integrated Sessions/

Poster Sessions17:00-18:30

Scientific Symposia/Oncopolicy Forum/

Society Session

19:15 - 21:00Opening Ceremony

18:45 - 20:15Satellite Symposia



Congress VenueMesse Wien Exhibition & Congress Centre

Messeplatz 1, 1021 Vienna, AustriaDetailed information about the venue:www.messe.at/en

Congress Secretariatc/o ECCO – the European CanCer OrganisationAvenue E. Mounier 83, B-1200 BrusselsTelephone: +32 (0)2 775 02 01Fax: +32 (0)2 775 02 00Email: [email protected]


Exhibition & SponsorshipThe 18th ECCO – 40th ESMO European Cancer Congress, Vienna, 25 – 29 September 2015, again combines the united efforts of all partner organisations to drive forward a multidisciplinary approach in an increasingly complex landscape with the ultimate aim of providing to each cancer patient the very best care and quality of life.

We invite you to be a part of this effort by showcasing your latest scientific data through this uniquely powerful platform of European and global oncology science and clinical practice.

For more information on advertising, sponsorship and exhibition opportunities:

Please contact: Bruno De Man - Phone: +32 (0)2 775 02 04.Email: [email protected]


6 7


European Cancer Congress 2015 Committees

Organising Committee

Martine Piccart Congress Chair, ECCO President

Rolf A. Stahel ESMO President

Peter Naredi Scientific Co-Chair

Elisabeth De Vries Scientific Co-Chair

Christoph Zielinski National Organising Committee Chair

Wim J.G. Oyen ECCO Treasurer

Executive Scientific Committee

Peter Naredi Scientific Co-Chair

Elisabeth De Vries Scientific Co-Chair

Philip Poortmans Radiation Oncology Vice Chair

Richard Marais Basic Science Vice Chair

Martine Piccart Congress Chair, ECCO President

Rolf A. Stahel ESMO President

Christoph Zielinski National Organising Committee Chair

Education Committee

Jean-Yves Douillard

Andrés Cervantes

Nikolaos Pavlidis

Michele Ghielmini

Giampaolo Tortora

Raffaele Califano

Claus-Henning Koehne

Robert Eckert

Florian Strasser

Richard Herrmann

Lorenz Jost

Karin Haustermans

Linda Wyld

Verena Jendrossek

Riccardo Riccardi

National Organising Committee

Christoph C. Zielinski

Walter Berger

Günter Gastl

Michael Gnant

Richard Greil

Wolfgang Hofer

Lukas A. Huber

Ulrich Jäger

Karin Kapp

Walter Klepetko

Ruth Ladenstein

Peter H. Lukas

Richard Pötter

Maria Sabilia

Hellmut Samonigg

Martin Schindl

Sebastian Schoppmann

Felix Sedlmayer

Veronika Sexl

Harald Titzer

Names in blue denote Chairs

8 9


Track Track

Names in blue denote Track Chairs

European Cancer Congress 2015Programme Tracks, Chairs and Experts

Track Track


Breast Cancer - Advanced Disease

Eniu Alexandru RO

Børresen-Dale Anne-Lise NO

Aebi Stefan CH

Brada Michael UK

Brouwers Adrienne H. NL

Caldas Carlos UK

Cardoso Fátima PT

Colleoni Marco IT

Fenlon Deborah UK

Leidenius Marjut FI

Zielinski Christoph C. AT

Breast Cancer - Early Disease

Wyld Lynda UK

Coles Charlotte E. UK

Di Leo Angelo IT

Brisken Catherine CH

Karlsson Per SE

Loibl Sibylle DE

Poortmans Philip NL

Sotiriou Christos BE

Viale Giuseppe IT

Wengström Yvonne SE

Yarnold John R. UK

Cancer Prevention and Screening

Cuzick Jack UK

Baildam Andrew D. UK

Storme Guy BE

Autier Philippe FR

Boyle Peter FR

Eeles Rosalind A. UK

La Vecchia Carlo IT

Central Nervous System Preusser Matthias AT

Combs Stephanie DE

Walker David UK

Soffietti Riccardo IT

Baumert Brigitta NL

Steeg Patricia S. US

Stupp Roger CH

van den Bent Martin J. NL

Wick Wolfgang DE

Clinical Trial Design and Regulatory Affairs

Dafni Urania GR

Kearns Pamela UK

Angenete Eva SE

Bogaerts Jan BE

Deutsch Eric FR

Litiere Saskia BE

Marsoni Silvia IT

Dittrich Christian AT

Siu Lillian L. CA

Early Drug Development Schellens Jan H.M. NL

Vens Conchita NL

von Kalle Christof DE

Aboagye Eric O. UK

Sessa Cristiana CH

Soria Jean Charles FR

Tabernero Josep ES

Twelves Chris UK

Gastrointestinal Malignancies - Colorectal Cancer

Tejpar Sabine BE

Rutten Harm NL

Valentini Vincenzo IT

Glynne-Jones Robert UK

Köhne Claus-Henning DE

Martling Anna SE

Ouwerkerk Jan NL

Oyen Wim J.G. NL

Van Cutsem Eric BE

Gastrointestinal Malignancies-Noncolorectal Cancer

Roviello Franco IT

Cunningham David UK

Morganti Alessio IT

Cervantes Andres ES

Ducreux Michel FR

Gruenberger Thomas AT

Lordick Florian DE

Verheij Marcel NL

Genitourinary Malignancies - Nonprostate Cancer

Escudier Bernard FR

de Reijke Theo NL

De Wit Ronald NL

Eisen Tim UK

Fanti Stefano IT

Gillessen Silke CH

Schmidinger Manuela AT

van As Nicholas UK

Genitourinary Malignancies - Prostate Cancer

Hoyer Morten DK

Cathomas Richard CH

Van Poppel Hendrik BE

De Bono Johann UK

Haustermans Karin BE

Khoo Vincent UK

Powles Thomas UK

Schalken Jack NL

Sternberg Cora N. IT

van Muilekom Erik NL

Gynaecological Cancer Rovirosa Angeles ES

Giavazzi Raffaella IT

Ray-Coquard Isabelle FR

Colombo Nicoletta IT

Dahm Kahler Pernilla SE

Banerjee Susana UK

Pötter Richard AT

Vergote Ignace B. BE

Haematological Malignancies

Ladetto Marco IT

Schrappe Martin DE

Ghielmini Michele CH

Montoto Silvia UK

Scheid Christof DE

Specht Lena DK

Stary Jan CZ

Head and Neck Cancer Langendijk Hans NL

Psyrri Amanda GR

Dietz Andreas DE

Giralt Jordi ES

Hainaut Pierre FR

Licitra Lisa IT

Noonan Brendan IE

Oosting Sjoukje NL

Oyen Wim J.G. NL

Immunotherapy of Cancer

Melero Ignacio ES

Galon Jerome FR

Jereczek-Fossa Barbara IT

Beckhove Philippe DE

Formenti Silvia US

Gerritsen Winald R. NL

Nathan Paul UK

Petrausch Ulf CH

Innovations in Radiation Oncology

Zips Daniel DE

Shiloh Yossi IL

Baumann Michael DE

Giammarile Francesco FR

Lara Pedro C. ES

Essers Marion NL

Wouters Brad CA

Lung Cancer - Localised/Local Regional Disease

Lievens Yolande BE

Veronesi Giulia IT

Dziadziuszko Rafal PL

Faivre-Finn Corinne UK

Novello Silvia IT

Shackcloth Michael UK

Senan Suresh NL

Smit Egbert F. NL

Vansteenkiste Johan BE

Verschuren Emmy FI

Lung Cancer - Metastatic Disease

Reck Martin DE

Kerr Keith UK

Buettner Reinhard DE

De Ruysscher Dirk BE

Felip Enriqueta ES

Margulies Anita CH

Mok Tony CN

Mordant Pierre FR

Peters Solange CH

Popat Sanjay UK

Melanoma and Skin Cancer

Marais Richard UK

Ascierto Paolo Antonio IT

Zoras Odysseas GR

Eggermont Alexander M.M. FR

Haanen John B.A.G. NL

Creutzberg Carien NL

Lorigan Paul UK

Michielin Olivier CH

Oncology Nursing Kelly Daniel UK

Ripamonti Carla IT

Bunskoek Sophie NL

Eicher Manuela CH

Fenlon Deborah UK

Titzer Harald AT

Margulies Anita CH

Moore Sally UK

Wells Mary UK

van Muilekom Erik NL

Wengström Yvonne SE

10 11


Regular Abstract Submission Regular abstracts can be submitted from 26 January 2015 using our specific online process which will be accessible on www.europeancancercongress.org. Abstracts will only be accepted if submitted through this process.

Regular abstract submission will close on 28 April 2015, at 21:00 Central European Time. Presenting authors are advised to submit their abstracts before the day of the deadline to help ensure safe receipt.

The Scientific Committee strongly encourages the submission of abstracts on Phase I, Phase II and large Phase III trials coming to an end or having new data available mid 2015.

Please note: more information about abstract preparation, topic categories, submission, policy and regulations will be published in the Advance Programme which will be available and published on www.europeancancercongress.org in early 2015.

Late-Breaking Abstract Submission A call for Late-Breaking Abstracts will be made in July 2015. Online submission will be open on www.europeancancercongress.org from 22 July 2015 until 5 August 2015.

Please note that placeholder abstracts should be submitted during the period of regular abstract submission with the understanding that additional data can be incorporated during the period of late-breaking abstract submission. However, if the data only becomes available for presentation after the general submission deadline, then complete abstracts without place holders can be submitted during the late-breaking submission period.

Late-breaking abstracts describe the latest advances that will change our daily clinical practice and have not been previously submitted. They should highlight novel and practice-changing studies. The late-breaking abstract deadline is not an extension of the general submission deadline. Focus is placed on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Congress.

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumour activity in a novel context; an early clinical trial with novel proof-of-principle data, or the demonstration of novel cancer biology with therapeutic implications – in each case the results should not have been fully available by the general abstract submission deadline. The data in the abstract cannot be published (manuscript or abstract) prior to the Congress.

If you have practice-changing data in the pipeline, the Executive Scientific Committee would be eager to discuss submission directly with you.

Please contact Davi Kaur by email for further details: [email protected]

Track Track


Oncopolicy Piccart Martine BE

Naredi Peter SE

Oyen Wim J.G. NL

Costa Alberto IT

Margulies Anita CH

Vassal Gilles FR

Celis Julio DK

Taphoorn Martin NL

Poortmans Philip NL

Audisio Riccardo UK

Stahel Rolf A. CH

Casali Paolo IT

Abrahamsson Per-Anders SE

Gregoire Vincent BE

Banks Ian BE

Paediatric Oncology Vassal Gilles FR

Bielack Stefan DE

Dieckmann Karin DE

Carrie Christian FR

Delattre Olivier FR

Ferrari Andrea IT

Kelly Daniel UK

Ladenstein Ruth AT

Pearson Andy UK

Rossig Claudia DE

Stark Daniel UK

Patient Advocacy Banks Ian BE

Bode Gerlind DE

Diler Sarper TR

Erdem Sema TR

Geissler Jan DE

Gore-Booth Jola UK

Kelly Joan IE

Oliver Kathy UK

Pelouchovà Jana CZ

Randsdorp Hans NL

Sarcoma: Soft Tissue and Bone

Blay Jean Yves FR

Bonvalot Sylvie FR

Haas Rick NL

Casali Paolo G. IT

Sandrucci Sergio IT

Juergens Heribert F. DE

Brugieres Laurence FR

Ferrari Andrea IT

Van der Graaf Winette NL

Supportive Care and Palliation

Charalambous Andreas CY

Poston Graeme UK

Ripamonti Carla IT

van der Linden Yvette NL

Bernot Marjana SI

Cherny Nathan I. IL

Kazmierska Joanna PL

Popescu Razvan CH

Sedlmayer Felix AT

Strasser Florian CH

Surgical Oncology Audisio Riccardo A. UK

Lichosik Danuta IT

Gonzalez-Moreno Santiago ES

Malik Hassan UK

Rubio Isabel T. ES

Sandrucci Sergio IT

Young Oncologists Banerjee Susana FR

Rouschop Kasper NL

van der Vorst Joost Renier NL

Califano Raffaele UK

Ozturk Mehmet Akif TR

Petrova Mila BG

Qvortrup Camilla DK

Schmid Maximillian AT

Sund Malin SE

12 13


Registration Fees

Early RateDeadline: Tuesday 7 April 2015

ECC 2015 Gross Rates

Early Rate Members 380

Early Rate Non Members 699

Early Rate Groups 699

Early Rate Junior Participants 175

Early Rate Emerging Economy 130

Early Rate Nurses Members 250

Early Rate Nurses Non-Members 375

Early Rate Patient Advocates 125

Regular RateDeadline: Tuesday 4 August 2015

Regular Rate Members 699

Regular Rate Non Members 999

Regular Rate Groups 999

Regular Rate Junior Participants 199

Regular Rate Emerging Economy -

Regular Rate Nurses Members 355

Regular Rate Nurses Non-Members 485

Regular Rate Patient Advocates 150

Late RateDeadline: Friday 18 September 2015

Late Rate Members 999

Late Rate Non Members 1099

Late Rate Junior Participants 220

Late Rate Emerging Economy -

Late Rate Nurses Members 460

Late Rate Nurses Non-Members 585

Late Rate Patient Advocates 170

Onsite RateDeadline: As of 19 September 2015

Onsite Rate Members/Non Members 1199

Onsite Rate Nurses Members/Non Members 685

Onsite Rate Junior Participants 235

Onsite Rate Patient Advocates 190

Day rate 355

General InformationAccommodation

Mondial Congress & Events has been appointed as the official local housing partner for the 18th ECCO – 40th ESMO European Cancer Congress and is offering hotel accommodation and other services for both groups and individuals.

Booking Accommodation for individuals will open on 1 October, 2014.

For all accommodation queries and information, please contact:

Mondial Congress & EventsOperngasse 20b1040 Vienna, AustriaTel: +43 1 58804 0Fax: +43 1 58804 185E-mail: [email protected]

We kindly ask you to contact the appointed local housing partner directly.The Congress secretariat cannot provide accommodation-related information or handle any such related requests.

Fellowship Grants

Through the generosity of the 18th ECCO – 40th ESMO European Cancer Congress Sponsors:

◼ 15 Fellowship Grants are offered to young oncology professionals (doctors, basic scientists, oncology nurses and radiotherapy technicians) from countries with lower-middle income economies as per World Bank classification

◼ 10 Fellowship Grants are offered to young oncology professionals from Eastern European countries

Detailed information on the grants, requirements and application procedure will be published on the Congress website: www.europeancancercongress.org

14 15


The Organising Committee gratefully acknowledges the support and collaboration of all Member Societies of ECCO, the European CanCer organisation, without which this Congress would not be possible.

Official Carrier

Save up to 20% on travel with the Star Alliance networkThe Star Alliance™ member airlines have been appointed as the Official Airline Network for the 18th ECCO – 40th ESMO European Cancer Congress, Vienna, 25 – 29 September 2015.

Registered participants travelling to the event may qualify for a Star Alliance Conventions Plus discount of up to 20%, depending on fare and class of travel booked. To obtain the discount, please quote the event code: OS13S15 when calling the reservation office of a participating Star Alliance member airline.

For booking office information please visit:www.staralliance.com/conventionsplus

The participating airlines for this event will be announced soon on the Congress website:


Discounts are offered on most published business and economy class fares, excludingwebsite/internet fares, senior and youth fares, group fares and Round the World fares.

Please note: For travel from Japan and New Zealand, special fares or discounts are offered by the participating airlines on their own network.

Congress Update Service

The Congress Update Service is the official electronic newsletter of the European Cancer Congress. It is specifically designed to share with you essential updates and notable developments in the lead up to the Congress.

Launching six months in advance, this monthly newsletter is sent to all registrants.

Please visit the website if you wish to subscribe:


Acknowledgements

FOUNDINGMEMBER

Fullmembers

Advisorymembers

European Associationfor Cancer Research

European OncologyNursing Society (EONS)

European Societyfor Medical Oncology

(ESMO)

European Society ofSurgical Oncology (ESSO)

European SocieTy for Radiotherapy & Oncology

(ESTRO)

European Societyof Paediatric Oncology

(SIOPE)

Breast International Group (BIG)

European Associationof Nuclear Medicine (EANM)

European Groupfor Blood and Marrow

Transplantation (EBMT)

Association of European Cancer Leagues (ECL)

European Breast Cancer Coalition (EUROPA DONNA)

EuropeanProstate Cancer Coalition

(EUROPA UOMO)

European Associationof Neuro-Oncology (EANO)

European Associationof Urology (EAU)

European Organisation for Research and treatment of

Cancer (EORTC)

European Society of Gynaecological Oncology

(ESGO)

European School ofOncology (ESO)

European Society of Oncology Pharmacy

(ESOP)

European Society of Breast Cancer Specialists

(EUSOMA)

European Society of SkinCancer Prevention

(EUROSKIN)

Flims Alumni Club (FAC) Myeloma PatientsEurope

Organisation of EuropeanCancer Institutes (OECI)

Union for International Cancer Control (UICC)

MYELOMAPATIENTSE U R O P E

MPe

The European Cancer Congress 2015, Vienna, 25 September - 29 September 2015

In partnership with ECCO, ESMO, ESTRO, ESSO, EACR, EONS, and SIOPE

ECCO, Avenue E. Mounier 83,B-1200 Brussels, Belgium

Phone: +32 (0)2 775 02 01Fax: +32 (0) 2 775 02 00


ECCO is taking its corporate responsibility efforts very seriously.This Announcement has been printed on paper made from 100% recycled fibres,using vegetable oil-based inks.